Literature DB >> 30680927

The Combination of Curcumin and Salsalate is Superior to Either Agent Alone in Suppressing Pro-Cancerous Molecular Pathways and Colorectal Tumorigenesis in Obese Mice.

Xian Wu1, Gar Yee Koh1, Yueyi Huang1,2, Jimmy W Crott1, Roderick T Bronson3, Joel B Mason1,2,4,5.   

Abstract

SCOPE: High-fat diets (HFDs) and adiposity increase colorectal cancer risk, in part by elevating pro-inflammatory cytokines that activate pro-cancerous signaling pathways. Curcumin (CUR), a dietary polyphenol and salsalate (SAL), an non-steroidal anti-inflammatory drug (NSAID) lacking the gastrotoxicity of aspirin, each suppress inflammatory signaling, but via different cellular pathways. METHODS AND
RESULTS: A/J mice (n = 110) are fed a low-fat diet (LFD, 10% kcal), a HFD (60% kcal), a HFD containing 0.4% CUR, a HFD containing 0.3% SAL, or a HFD containing both agents (CUR/SAL). All mice receive six injections of azoxymethane. Compared to LFD-fed mice, HFD-fed mice display elevated colonic cytokines, crypt cell proliferation, and increased tumorigenesis (p < 0.05). CUR/SAL significantly reduces colonic cytokines (p < 0.01), suppresses activation of the PI3K/Akt/mTOR/NF-κB/Wnt pathways (p < 0.01), activates AMPK (p < 0.01), attenuates abnormal proliferation of the colonic mucosa (p < 0.05), and reduces tumor multiplicity and burden (p < 0.05), in comparison to the HFD control. In contrast, CUR or SAL alone does not suppress abnormal crypt cell proliferation or tumor multiplicity, and is largely ineffective in modifying activation of these signaling pathways.
CONCLUSION: These observations demonstrate the superiority of the CUR/SAL over the individual agents and provide a scientific basis for future translational studies in obese subjects and/or those habitually consuming HFDs.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  PI3K/Akt/mTOR/NF-κB; colorectal cancer; curcumin; high-fat diet; salsalate

Mesh:

Substances:

Year:  2019        PMID: 30680927     DOI: 10.1002/mnfr.201801097

Source DB:  PubMed          Journal:  Mol Nutr Food Res        ISSN: 1613-4125            Impact factor:   5.914


  6 in total

1.  Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy.

Authors:  Sajad Fakhri; Seyed Zachariah Moradi; Akram Yarmohammadi; Fatemeh Narimani; Carly E Wallace; Anupam Bishayee
Journal:  Front Oncol       Date:  2022-03-01       Impact factor: 6.244

2.  Weight Loss and/or Sulindac Mitigate Obesity-associated Transcriptome, Microbiome, and Protumor Effects in a Murine Model of Colon Cancer.

Authors:  Laura W Bowers; Elaine M Glenny; Arunima Punjala; Nadia A Lanman; Audrey Goldbaum; Caroline Himbert; Stephanie A Montgomery; Peiying Yang; Jatin Roper; Cornelia M Ulrich; Andrew J Dannenberg; Michael F Coleman; Stephen D Hursting
Journal:  Cancer Prev Res (Phila)       Date:  2022-08-01

Review 3.  The Functional Role of Lactoferrin in Intestine Mucosal Immune System and Inflammatory Bowel Disease.

Authors:  Ning Liu; Gang Feng; Xiaoying Zhang; Qingjuan Hu; Shiqiang Sun; Jiaqi Sun; Yanan Sun; Ran Wang; Yan Zhang; Pengjie Wang; Yixuan Li
Journal:  Front Nutr       Date:  2021-11-25

Review 4.  Inhibition and potential treatment of colorectal cancer by natural compounds via various signaling pathways.

Authors:  Mingchuan Wang; Xianjun Liu; Tong Chen; Xianbin Cheng; Huijie Xiao; Xianglong Meng; Yang Jiang
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

Review 5.  Classifying the Linkage between Adipose Tissue Inflammation and Tumor Growth through Cancer-Associated Adipocytes.

Authors:  Yae Chan Song; Seung Eon Lee; Young Jin; Hyun Woo Park; Kyung-Hee Chun; Han-Woong Lee
Journal:  Mol Cells       Date:  2020-09-30       Impact factor: 5.034

Review 6.  Therapeutic Potential of Naturally Occurring Small Molecules to Target the Wnt/β-Catenin Signaling Pathway in Colorectal Cancer.

Authors:  Luiz F S Oliveira; Danilo Predes; Helena L Borges; Jose G Abreu
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.